Teva Preserves Azilect’s Patent Even After FDA Rejects Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Court rules Mylan failed to prove the Azilect patent is invalid; expert testifies drug is “more likely than not” to slow Parkinson’s disease progression, even if FDA remains unconvinced.